Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan after primary angioplasty in ST-segment elevation myocardial infarction
2017-003843-39Phase 3Completed
- Sponsor
- Hospital Universitario de Canarias
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute ST-segment elevation myocardial infarction (STEMI) and acute coronary syndrome (ACS) comparing Levosimendan with Placebo (2 arms). Primary endpoint: Infarct size by cardiac magnetic resonance. Started Jan 2018; status: completed.
02
Drugs
levosimendan
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2017-003843-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003843-39.